The FARP1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the Raji human B lymphocyte cell line. This model features disruption of the FARP1 gene, which encodes a Rac1-specific guanine nucleotide exchange factor (GEF). The polyclonal format results from non-clonal expansion after CRISPR/Cas9-mediated gene targeting, providing a heterogeneous pool of FARP1-null alleles without single-cell isolation.
The Raji cell line is an Epstein-Barr virus (EBV)-positive B lymphocyte line established from a Burkitt lymphoma patient. Raji cells grow in suspension and are extensively used to study B-cell biology, lymphomagenesis, and hematologic malignancies. Their stable growth and transformed phenotype make them amenable to gene knockout studies, but the EBV-positive background may modulate certain signaling networks.
FARP1 functions as a Rac1-specific GEF activated downstream of semaphorin-plexin receptor binding, with direct interactions documented for Plexin-A1 and Plexin-A4. Upon receptor engagement, FARP1 promotes GDP/GTP exchange on Rac1, initiating signaling cascades that involve PAK1 and lead to actin filament assembly, focal adhesion turnover, and cell motility. FARP1 also participates in crosstalk with receptor tyrosine kinases and contributes to axonal guidance mechanisms. By coupling extracellular signals to cytoskeletal reorganization, FARP1 plays a pivotal role in cell adhesion and directed migration.
In the Raji B lymphocyte context, FARP1 knockout impairs Rac1-mediated signal transduction, compromising the cell??s capacity to remodel the actin cytoskeleton in response to microenvironmental stimuli. This model is particularly suited for examining the roles of Rho GTPase signaling in B-cell adhesion, migration, and lymphoma pathophysiology. Loss of FARP1 may attenuate responses to chemotactic and cell?Ccell adhesion cues, offering a platform to dissect pathways underlying malignant B-cell behavior.
Researchers can employ this polyclonal knockout population in Western blotting to assess Rac1-GTP levels and PAK1 phosphorylation, immunofluorescence to visualize actin structures, and cell adhesion/migration assays to quantify functional deficits. Flow cytometry permits analysis of surface receptor expression, while RT-qPCR confirms FARP1 transcript disruption. These applications support investigations into semaphorin signaling in lymphocytes, Rho GTPase biology in cancer, and actin regulation in B cells. For additional information, contact Ascent Research.
